Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;28(2):55-59.
doi: 10.4078/jrd.2021.28.2.55.

Axial Spondyloarthritis: Current Advances, Future Challenges

Affiliations
Review

Axial Spondyloarthritis: Current Advances, Future Challenges

Robert D Inman. J Rheum Dis. .

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory joint disease with a predilection for the spine. It affects young adults and has the potential to have a major impact on quality of life, not only because of the chronic pain and fatigue, but also because of the potential for marked disability related to spinal ankylosis. Early detection of axSpA remains a major challenge, for which there is a heightened sense of urgency since it has been shown that earlier intervention with biologics can alter the progression of radiographic change in the spine. Advances in the genetics of axSpA have highlighted a number of candidate genes conferring susceptibility to the disease, but there is evidence of environmental factors playing a role as well. Recently studies in both clinical and experimental axSpA have implicated alterations in the gut microbiome as playing a key role, and the immunology of the gut-joint axis is becoming better understood. The unmet needs which are shaping the research agenda include improvement in early case identification, sensitive and specific biomarkers which could accurately reflect disease activity and severity, improved understanding of the common pathways of inflammation in the skin, eye and gut in axSpA, and novel therapeutic targets which could have curative potential.

Keywords: Ankylosing spondylitis; Spondylitis; Unmet needs.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

References

    1. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–54. doi: 10.1002/art.38070. - DOI - PMC - PubMed
    1. Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, et al. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis. 2020;79:1327–32. doi: 10.1136/annrheumdis-2019-216741. - DOI - PubMed
    1. Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2014;73:1873–9. doi: 10.1136/annrheumdis-2013-203630. - DOI - PubMed
    1. Akram A, Lin A, Gracey E, Streutker CJ, Inman RD. HLA-B27, but not HLA-B7, immunodominance to influenza is ERAP dependent. J Immunol. 2014;192:5520–8. doi: 10.4049/jimmunol.1400343. - DOI - PubMed
    1. Tavasolian F, Rashidi M, Hatam GR, Jeddi M, Hosseini AZ, Mosawi SH, et al. HLA, immune response, and susceptibility to COVID-19. Front Immunol. 2021;11:601886. doi: 10.3389/fimmu.2020.601886. - DOI - PMC - PubMed

LinkOut - more resources